Logo

Indications - Locally advanced or metastatic non-small cell lung carcinoma, Locally advanced, unresectable or metastatic pancreatic cancer

Dosage & Administration - Oral (Adult)- Locally advanced or metastatic non-small cell lung carcinoma: 150 mg once daily until disease progression or unacceptable toxicity. Reduce dose in decrements of 50 mg when necessary. Locally advanced, unresectable or metastatic pancreatic cancer: As 1st-line treatment with gemcitabine: 100 mg once daily, reduce dose in decrements of 50 mg when necessary. Patient on CYP3A4 or CYP1A2 inhibitor: Reduce dose in decrements of 50 mg when necessary. Smokers or patient on CYP3A4 inducer: Increase dose as tolerated in increments of 50 mg at 2-wk intervals. Administration Should be taken on an empty stomach. Take at least 1 hr before or 2 hr after meals.

Side Effects - Rash manifests as a mild or moderate erythematous and papulopustular rash. Bullous, blistering, and exfoliative skin conditions, diarrhoea, nausea, vomiting, stomatitis, GI bleeding, abdominal pain, anorexia, alopecia, pruritus, dry skin, paronychia, conjunctivitis, epistaxis, fatigue, alterations in LFT, abnormal eyelash growth, bilateral eardrum perforation, keratoconjunctivitis sicca or keratitis.

Contraindications - Contraindicated in pregnancy, hypersensitivity

Others - Pregnancy & Lactation Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). Precautions & Warnings Hepatic and renal impairment. Interrupt or discontinue therapy if patient develops unexplained pulmonary symptoms (e.g. dyspnoea, cough, fever), GI perforation, severe bullous, skin or ocular disorders, if dehydration occurs (esp in at-risk patients). Pregnancy and lactation. LFT (e.g. serum transaminase, bilirubin, alkaline phosphatase) should be periodically monitored. Renal function and electrolytes should be monitored periodically in patients at risk of dehydration. Overdose Effects Symptoms: Diarrhoea, rash, and liver transaminase elevation. Management: Symptomatic and supportive treatment. Storage Conditions Store between 15-30°C.